What is the optimal duration of immune checkpoint inhibitors in malignant tumors?

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has made a revolutionary difference in the treatment of malignant tumors, and considerably extended patients’ overall survival (OS). In the world medical profession, however, there still reaches no clear consensus on the optimal dura...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jiaxin, Song, Yuxiao, Tang, Jiazhuo, Zhang, Bicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548621/
https://www.ncbi.nlm.nih.gov/pubmed/36225926
http://dx.doi.org/10.3389/fimmu.2022.983581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548621/
https://www.ncbi.nlm.nih.gov/pubmed/36225926
http://dx.doi.org/10.3389/fimmu.2022.983581

Ejemplares similares